08:49 AM EDT, 07/09/2025 (MT Newswires) -- Revolution Medicines ( RVMD ) and Iambic Therapeutics said Wednesday they have entered a multi-year agreement to discover new drug candidates using AI-driven models.

Under the agreement, Iambic will train customized versions of its AI models using proprietary structures and molecular libraries provided by Revolution Medicines ( RVMD ), the company said.

Both companies will gain access to the enhanced tools, with rights to pursue select exclusive targets independently, Revolution Medicine said.

Iambic will receive up to $25 million in upfront and near-term milestone payments, along with research and development reimbursements, the companies said.

Shares of Revolution Medicines ( RVMD ) were over 1% higher in recent premarket activity.